ACTU (Actuate Therapeutics) Shares Outstanding (EOP): 23.71 Mil (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Shares Outstanding (EOP)?

Actuate Therapeutics ACTU -14.29% 14 Shares Outstanding (EOP) is 23.71 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Actuate Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 23.71 Mil.

Actuate Therapeutics's quarterly shares outstanding increased from Dec. 2025 (23.25 Mil) to Mar. 2026 (23.71 Mil). It means Actuate Therapeutics issued new shares from Dec. 2025 to Mar. 2026 .

Actuate Therapeutics's annual shares outstanding increased from Dec. 2024 (19.53 Mil) to Dec. 2025 (23.25 Mil). It means Actuate Therapeutics issued new shares from Dec. 2024 to Dec. 2025 .


Actuate Therapeutics  (NAS:ACTU) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Actuate Therapeutics Shares Outstanding (EOP) Related Terms


Actuate Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Shares Outstanding (EOP) Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
19.11 19.11 19.53 23.25

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.53 20.47 23.24 23.25 23.71

ACTU vs AURX, ESLA, MGX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Actuate Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Shares Outstanding (EOP) falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 23.71 Mil mean?
Actuate Therapeutics (ACTU) has a Shares Outstanding (EOP) of 23.71 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Shares Outstanding (EOP) too high?
Actuate Therapeutics' current Shares Outstanding (EOP) is 23.71 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Shares Outstanding (EOP) compare to AURX and ESLA?
Actuate Therapeutics' Shares Outstanding (EOP) of 23.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Shares Outstanding (EOP) is 23.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Shares Outstanding (EOP) of 23.71 Mil. The current Shares Outstanding (EOP) is 23.71 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Shares Outstanding (EOP) is 23.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price